Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$3.58 USD
-0.05 (-1.38%)
Updated Jun 14, 2024 10:10 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Eton Pharmaceuticals, Inc. [ETON]
Reports for Purchase
Showing records 21 - 37 ( 37 total )
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Power Trio Product Potential in Neurological Disorders; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alkindi Sprinkle Approval on Schedule; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alaway Approval at Long Last; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Senior Vice President of Scientific Affairs Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Products May Launch Near-Term; 2Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alkindi Sprinkle in Spotlight; Estimate Changes; Reducing PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Alkindi Sprinkle Deals Adds an Arrow to the Quiver; Raising PT to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive ET-101 Results; ET-105 Resubmission Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2019 Financial Results Reported; Revenue Ramp in 2020; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Xellia Should Accelerate Biorphen Adoption; Reiterate Buy; Raising PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple 2020 Commercial Inflection Points; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biorphen Approval on Schedule; Launch Next; Reiterate Buy and Raising Target to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Lower-Than-Projected R-D Spending; Catalyst-Rich Period Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ET-105 Filing Accepted; Approval Decision Date Assigned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
EM-100 Complete Response Letter Non-Impactful; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Lamotrigine Oral Liquid Candidate Licensing Transaction Provides Near-Term Boost; Reiterate Buy; Raising Target to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A Quiver Full of Arrows; Initiating at Buy and $15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R